Commercial Technician 2

Nuclera appoints Carl Raimond as Chief Executive Officer. * Former Olink Proteomics President brings extensive life-science tools leadership experience, having helped lead Olink through its $3.1 billion acquisition by Thermo Fisher Scientific * Co-founder and former CEO Dr Michael Chen transitions to Chief Scientific and Business Officer Cambridge, UK, and Boston, MA, USA, 22 September 2026: Nuclera, the biotechnology company enabling access to innovative protein technologies, today announced the appointment of Carl Raimond as Chief Executive Officer, effective immediately. Dr Michael Chen, Nuclera's co-founder and former CEO, transitions to the role of Chief Scientific and Business Officer, continuing to provide scientific leadership while supporting market development and strategic partnerships. The leadership transition marks the next phase in Nuclera's evolution as the Company builds on more than a decade of expertise in cell-free protein synthesis, digital microfluidics and protein production. The combination of Carl's experience scaling life-science businesses with Michael's scientific leadership and deep understanding of Nuclera's technology and markets will support the Company as it expands adoption of its platform across priority life-science workflows. Nuclera is applying its cell-free protein synthesis and digital microfluidics capabilities to accelerate the speed of protein science, with current focus areas including full-length IgG antibody screening, challenging membrane protein synthesis, and soluble protein expression. In May 2026, the Company launched antibody service capabilities to support early experimental triage for antibody discovery programs, complementing its eProtein Discovery(TM) system for in-house protein expression and screening. The Company is also extending its antibody strategy beyond centralized service delivery. Nuclera is advancing early partner work toward customer-site antibody screening workflows, designed to bring cell-free expression and binding triage closer to AI-enabled discovery teams and reduce the delay between computational design and experimental evidence. Carl joins Nuclera from Thermo Fisher Scientific, where he served as President of Proteomic Sciences following its acquisition of Olink Proteomics. He previously served as President of Olink Proteomics, helping lead the company through its $3.1 billion acquisition by Thermo Fisher Scientific in 2023. An experienced life-sciences executive, Carl has also held senior leadership roles at PerkinElmer, Agilent Technologies and Affymetrix. As Chief Scientific and Business Officer, Michael will focus on scientific strategy, market development and strategic partnerships, working closely with Carl as the Company enters its next phase of growth whilst maintaining continuity in Nuclera's scientific direction. Carl Raimond, CEO at Nuclera, said: "Nuclera has built a differentiated technology platform at the intersection of cell-free protein synthesis, digital microfluidics, and protein discovery. I'm excited to join the Company as we sharpen our focus on customer adoption, commercial execution, and expanding applications of our technology across life-science workflows. Michael's scientific leadership remains central to Nuclera's future, and I look forward to working with him and the team to translate this strong technology foundation into impactful solutions for our customers." Dr Michael Chen, co-founder and Chief Scientific and Business Officer at Nuclera, commented: "As a structural biologist, I know firsthand the time and frustration protein production can cost a development program. That frustration is part of why we started Nuclera. I'm incredibly proud of what the team has built and the difference our technology is already making for protein scientists. Now, we've reached an important point in the Company's evolution, and Carl is the right CEO to lead us forward. Carl's experience building and scaling life-science businesses, combined with his understanding of the opportunity ahead, will be a huge asset to Nuclera. I'm excited to work alongside him to bring that impact to every benchtop."

Nuclera appoints ex-Thermo Fisher exec Carl Raimond as CEO. Business Weekly 22 Sep 2026 Cambridge biotech company Nuclera has appointed Carl Raimond as CEO in a move that sees co-founder Dr Michael Chen transition to the role of Chief Scientific and Business Officer. The company says the leadership change marks the next phase in Nuclera's evolution as it builds on more than a decade of expertise in cell-free protein synthesis, digital microfluidics and protein production. Raimond joins Nuclera from Thermo Fisher Scientific, where he served as President of Proteomic Sciences following its acquisition of Olink Proteomics. He previously served as President of Olink Proteomics, helping lead the company through its $3.1 billion acquisition by Thermo Fisher Scientific in 2023. As Chief Scientific and Business Officer, Dr Michael Chen will focus on scientific strategy, market development and strategic partnerships. Raimond said: "Nuclera has built a differentiated technology platform at the intersection of cell-free protein synthesis, digital microfluidics, and protein discovery. I'm excited to join the Company as Cambridge Innovation Capital plc sharpen its focus on customer adoption, commercial execution, and expanding applications of its technology across life-science workflows. "Michael's scientific leadership remains central to Nuclera's future, and I look forward to working with him and the team to translate this strong technology foundation into impactful solutions for our customers." Nuclera is applying its cell-free protein synthesis and digital microfluidics capabilities to accelerate the speed of protein science, with current focus areas including full-length IgG antibody screening, challenging membrane protein synthesis, and soluble protein expression. In May 2026, the Company launched antibody service capabilities to support early experimental triage for antibody discovery programs, complementing its eProtein Discovery(TM) system for in-house protein expression and screening. The Company is also extending its antibody strategy beyond centralised service delivery. Nuclera is advancing early partner work toward customer-site antibody screening workflows, designed to bring cell-free expression and binding triage closer to AI-enabled discovery teams and reduce the delay between computational design and experimental evidence. Dr Chen said: "As a structural biologist, I know firsthand the time and frustration protein production can cost a development program. That frustration is part of why Cambridge Innovation Capital plc started Nuclera. I'm incredibly proud of what the team has built and the difference its technology is already making for protein scientists. "Now, we've reached an important point in the Company's evolution, and Carl is the right CEO to lead us forward. Carl's experience building and scaling life-science businesses, combined with his understanding of the opportunity ahead, will be a huge asset to Nuclera. I'm excited to work alongside him to bring that impact to every benchtop."

Mayo Clinic and Thermo Fisher Scientific have launched Precure, LLC to identify early biological signs of disease before symptoms appear. Mayo Clinic will be the majority owner, with Thermo Fisher as a minority partner. The venture will create one of the world's largest biomedical datasets by generating multi-omics data from one million biospecimens. It will integrate proteomic, genomic and longitudinal clinical data to help researchers identify early disease signals across conditions including cancer, cardiometabolic disease, neurological disorders and immune-mediated diseases. Mayo Clinic will contribute clinical expertise, biospecimens and de-identified patient data. Thermo Fisher will provide proteomics technology, including its Olink Explore HT platform and Orbitrap Mass Spectrometry systems. The initiative will use advanced AI and data analytics to identify patterns and translate findings into actionable insights.